Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET

Koo, Phillip J.; Kwak, Jennifer; Pokharel, Sajal S.; Choyke, Peter L.

doi:10.1007/s11912-015-0480-y

Cited by 15 publications

(11 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most focal therapy strategies rely on mpMRI and saturation biopsy techniques, such as transperineal mapping biopsies ; however, it is accepted that mpMRI will miss a proportion of clinically significant prostate cancers . A promising way to augment this approach is to combine information from mpMRI with molecular information derived from positron emission tomography (PET) . To date, mpMRI has typically focussed on local staging, whilst PET has focussed on detecting metastatic disease .…”

Section: Introductionmentioning

confidence: 99%

Voxel‐wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework

et al. 2019

View full text Add to dashboard Cite

ObjectivesTo develop a registration framework for correlating positron emission tomography/computed tomography (PET/CT) images with multiparametric magnetic resonance imaging (mpMRI) and histology of the prostate, thereby enabling voxel-wise analysis of imaging parameters. Patients and MethodsIn this prospective proof-of-concept study, nine patients scheduled for radical prostatectomy underwent mpMRI and PET/CT imaging before surgery. One had PET imaging using 18

show abstract

Section: Introductionmentioning

confidence: 99%

Voxel‐wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Newly developed tracers exhibit increased accuracy for the detection of small, incipient metastatic foci [28][29]. Improvements in MRI techniques, and particularly in functional imaging, have enabled radiologists to play an important role in the risk stratification and management of patients [30][31][32]. 18 F-FDG PET/CT is primarily useful in the diagnosis and staging of prostate cancer because it combines the metabolic information of PET with the anatomic information of CT.…”

Section: Discussionmentioning

confidence: 99%

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Luo

Ruan

Pang

et al. 2019

Preprint

View full text Add to dashboard Cite

Oncology 2 KEYWORDS positron emission tomography/computed tomography, prostate cancer, percutaneous trans-pararectal space prostate biopsy Abstract Background: Biopsy is considered the gold-standard technique for prostate cancer diagnosis and is recommended in patients with a high clinical indication of prostate cancer. In this study, we aimed to determine the diagnostic efficacy of a novel positron emission tomography (PET)/computed tomography (CT)-guided percutaneous trans-pararectal space-based approach to targeted prostate biopsy. Methods: PET/CT-guided percutaneous trans-pararectal space prostate biopsies were performed in 14 consecutive patients with indications of prostate cancer. Whole-body 18F-FDG PET/CT indicated the presence of 18F-fluorodeoxyglucose (FDG)-avid focal prostate lesions. Two tissue specimens were obtained from each patient. The final diagnoses were established based on the results of a histopathological analysis and clinical follow-up, and these findings were used to verify the diagnostic accuracy of 18F-FDG PET/CT for prostate cancer. Results: The diagnostic accuracy of 18F-FDG PET/CT for prostate cancer was 81.8%. Further analyses of the two biopsied samples per patient led to confirmed histopathological and immunohistochemical diagnoses of prostate cancer in all 14 patients. Consequently, the success rate of PET/CT-guided percutaneous trans-pararectal space prostate-targeted biopsy for the diagnosis of prostate cancer was 100.0% (14/14). Regarding safety, the average duration of biopsy was 20 min, and no serious complications occurred.Conclusions: PET/CT-guided percutaneous trans-pararectal space prostate biopsy may yield a new approach to targeted prostate biopsy for the diagnosis of prostate cancer. Moreover, this biopsy procedure can be performed safely without complications, and is more cost-effective than conventional trans-rectal and trans-perineal prostate biopsy methods.

show abstract

“…GRP binds to 7-transmembrane G-protein coupled receptor which promote tumor growth (74). High GRP receptor (GRPR) overexpression is present in many different cancers, such as breast, lung, urinary tract and prostate.…”

Section: Bombesin/gastrin-releasing Peptidementioning

confidence: 99%

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Bednarova

Lindenberg

Vinsensia

et al. 2017

Transl. Androl. Urol.

Self Cite

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa. However, some PET agents have shown remarkable promise in staging high-risk PCa (defined as any combination of a clinical T3, a PSA score >20 ng/mL, or a Gleason score of 8–10), as well as biochemical relapse after definitive therapy and metastatic PCa. PET agents can be divided into those that interrogate tumor metabolism (18F-FDG, 11C-Choline, 18F-Choline, 11C-Acetate, 18F-FACBC), hormone receptors (18F-FDHT), and other targets such as prostate specific membrane antigen (PSMA) (68Ga-PSMA, 18F-DCFBC, 18F-DCFPyl) or gastric releasing peptide (18F-GRP or 18F-Bombesin). In this review, we compare the available PCa targeted PET tracers utilized in staging of high risk tumors.

show abstract

Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET

Cited by 15 publications

References 74 publications

Voxel‐wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework

Voxel‐wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Contact Info

Product

Resources

About